IL-13 induces a CD45 checkpoint in intestinal tuft cells

What the work claims

The authors identify CD45, the receptor tyrosine phosphatase encoded by Ptprc, as a tuft-cell-intrinsic regulator of intestinal type 2 immunity. Their central claim is that IL-13, the key cytokine secreted by group 2 innate lymphoid cells and T helper 2 cells during anti-parasite responses, induces CD45 expression in intestinal tuft cells as a negative feedback loop. Once induced, CD45 restrains tuft cell activation, dampens downstream ILC2 and Th2 responses, and limits parasite clearance. The work combines an epithelial-specific CD45 knockout mouse, helminth infection, bulk transcriptomics, proteomics, and intestinal organoid cultures to argue that CD45 is a druggable epithelial checkpoint for type 2 inflammatory disease.¹

How it works

Tuft cells are rare chemosensory epithelial cells that initiate type 2 immunity by releasing IL-25, which activates ILC2s and promotes Th2 responses. Those immune cells then secrete IL-13, which feeds back on epithelial progenitors to expand tuft and goblet cell lineages. This amplification loop needs a brake to prevent excessive inflammation in a tissue that is continuously exposed to microbiota and dietary antigens.

The authors re-analyzed a published single-cell atlas of mouse small intestinal epithelium and found that Ptprc, the gene encoding CD45, is expressed almost exclusively in tuft cells and is concentrated in the tuft-2 subset, which has an immune-enriched transcriptional program. Protein validation by flow cytometry and immunofluorescence showed that CD45-positive tuft cells are rare in the proximal small intestine but abundant in the distal small intestine, where microbial density is highest. CD45 localizes to the apical surface of tuft cells, facing the intestinal lumen, a position consistent with sensing luminal signals.

To test function, the authors generated an inducible epithelial-specific CD45 knockout by crossing Ptprc floxed mice with Villin-CreERT2 animals. After tamoxifen, CD45 was efficiently deleted in tuft cells without altering tuft cell abundance or gross tissue architecture. At homeostasis, CD45-deficient tuft cells upregulated inflammatory and stress pathways, including NF-kappaB, TNF, Toll-like receptor, and IL-17 signaling. The broader epithelium also shifted toward an inflammatory state, with increased expression of RELMbeta and other type 2-linked effectors. Eosinophil frequencies roughly doubled, while ILC2 and Th2 cell numbers were unchanged at baseline.

During infection with the helminth Heligmosomoides polygyrus bakeri, CD45 expression in wild-type tuft cells rose from about 21% to 42%. CD45-deficient mice mounted a stronger type 2 response: expanded ILC2 and Th2 cells, reduced Th1 cells, fewer Foxp3-positive GATA3-positive regulatory T cells, and increased eosinophils. These mice also carried fewer adult worms, consistent with an unrestrained anti-parasite response.

The organoid experiments clarify where CD45 acts. In distal small intestinal organoids treated with IL-13 for 72 hours, CD45 deletion did not alter tuft cell differentiation or the balance of tuft-1 versus tuft-2 signatures. Instead, CD45-deficient organoids displayed a 40-gene activation signature shared with CD45-deficient tuft cells in vivo and with IL-13-treated wild-type organoids. The signature was enriched for TNFalpha-NFkappaB signaling and protein dephosphorylation. Low-input mass spectrometry of only 500 sorted tuft cells further linked CD45 loss to decreased IL-17rb, a receptor subunit that attenuates type 2 immunity, and increased STAT5a, which has been proposed to enhance type 2 responses. Finally, IL-13 treatment induced Ptprc about 30-fold in organoids, an effect blunted in epithelial IL-13 receptor alpha 1 knockouts, establishing IL-13 as a direct upstream inducer.¹

Where a skeptic should push

The most load-bearing assumption is that CD45's effect in tuft cells is direct and specific, rather than a secondary consequence of broadly derepressed epithelial inflammation. CD45 is a phosphatase with many potential substrates, and its deletion could alter signaling networks well beyond a single checkpoint. The authors identify IL-17rb downregulation and STAT5a upregulation as candidate mediators, but they do not demonstrate that restoring IL-17rb or blocking STAT5 rescues the phenotype, so causality remains speculative.

Several observations complicate a simple model. At homeostasis, CD45 deletion causes epithelial inflammation and eosinophilia without increasing ILC2 or Th2 cells, the canonical drivers of type 2 immunity. This suggests that part of the phenotype may be tuft-cell-autonomous or mediated by non-lymphocyte mechanisms, rather than a clean ILC2-Th2 circuit. During infection, the stronger type 2 response is accompanied by reduced worm burden, which is consistent with CD45 as a brake but also raises the possibility that the knockout mice have a generally lower activation threshold for multiple anti-parasite programs.

The human relevance is promising but incomplete. The authors show that published human intestinal single-cell data also enrich PTPRC in ileal tuft cells and express the IL-13 sensing machinery, but they do not validate function in human organoids. Because the paper is a preprint, the claims have not yet been peer reviewed. The sample sizes for some experiments, such as the low-input proteomics, are also small.

Implication for intestinal organoid models of type 2 immunity

For organoid models of human organs, the paper is valuable because it uses intestinal organoids to separate two processes that are coupled in vivo: tuft cell differentiation and tuft cell activation. The authors show that IL-13 drives both differentiation and CD45 induction, but CD45 deletion affects only the activation state, not the number or subtype identity of tuft cells. That dissociation is methodologically important. It means organoids can be used to study signaling thresholds and inflammatory priming in a controlled epithelial system without the confounding presence of immune cells or parasites.

The drug-discovery opportunity is to target the CD45-IL-13 feedback axis in type 2 inflammatory diseases. Inflammatory bowel disease, food allergy, asthma, and helminth infection all involve excessive or misdirected type 2 responses. If CD45 induction normally limits these responses, then small molecules or biologics that enhance CD45 phosphatase activity or mimic its downstream brake could be anti-inflammatory. Conversely, blocking CD45 might be useful in situations where stronger type 2 immunity is desired, such as vaccine adjuvants or anti-parasite therapies, although the systemic immune effects of CD45 modulation would need careful management.

The threat is that CD45 is not an easy drug target. It is a large receptor phosphatase with multiple isoforms and broad expression in hematopoietic cells. Therapeutic modulation risks off-target immune suppression or activation. Moreover, the beneficial effect of CD45 deletion in clearing parasites suggests that inhibiting CD45 in the gut could have context-dependent consequences, including enhanced inflammation rather than reduced inflammation depending on the stimulus.

The less obvious implication is for organoid coculture design. Current intestinal organoids lack immune cells, which is exactly why this study could isolate an epithelial checkpoint. But the full type 2 circuit requires ILC2s, Th2 cells, and eosinophils. Building organoid-immune cocultures that include these partners, while measuring CD45 dynamics, would move the model from mechanism to therapeutic prediction. The paper provides a clear molecular readout, the CD45-IL-13 induction ratio, that could score candidate modulators in such a system.

The bottom line

This is a mechanistic preprint that identifies CD45 as an epithelial checkpoint in intestinal tuft cells and links it to IL-13-driven type 2 immunity. The combination of mouse genetics, infection biology, transcriptomics, proteomics, and organoid work makes the case unusually broad for a single study. What would confirm its therapeutic relevance is functional validation in human intestinal organoids, demonstration that modulating CD45 or its downstream targets changes disease-relevant outcomes, and a clearer understanding of which phosphatase substrates mediate the brake. What would weaken it is evidence that the phenotype is caused by generalized epithelial stress rather than a specific CD45-dependent circuit. For now, it is best read as a new candidate pathway for type 2 immune regulation that organoid models are well positioned to explore.